1 / 7

NeuroPace RNS System

NeuroPace RNS System. Rachel McAteer BME 281. Intro : Used to treat medically refractory partial epilepsy Refractory epilepsy : Frequent severe seizures that significantly lower the quality of life Poorly controlled b y medication, if at all Partial epilepsy :

amos-bishop
Download Presentation

NeuroPace RNS System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NeuroPace RNS System Rachel McAteer BME 281

  2. Intro: • Used to treat medically refractory partial epilepsy • Refractory epilepsy: • Frequent severe seizures that significantly lower the quality of life • Poorly controlled by medication, if at all • Partial epilepsy: • Onset of seizures can be localized to a specific area of the brain

  3. RNS System –Two Main Components • Neurostimulator [internal] • Small battery-powered device • Surgically implanted within the cranium • Two leads (electrodes) – Cortical Strip Lead, Depth Lead • Programmer[external] • Telementary wand • Laptop (USB connection) – containing program

  4. How it works: • Leads are implanted on areas of the brain where seizures are suspected to originate • When abnormal electrical activity is detected, the leads deliver electrical stimulation to normalize brain activity • Telementary wand is held over implantation site to retrieve information • Wand is then attached via USB to laptop/program by Programmer

  5. Results: • 191 adults tested • Two groups, 1:1, double-blind • After 12 weeks: • Group receiving stimulation – 37.9% reduction in seizure frequency • Group not receiving stimulation – 17.3% reduction in seizure frequency • Both groups received stimulation for 84 weeks • 2 year follow-up – 50% or greater reduction in seizures

  6. Recently granted pre-market approval by the FDA* • Benefits: Consistently proven to increase the quality of life in patients suffering from refractory partial epilepsy without negative neurological side effects. • Risks: • Standard surgical risks (i.e. infection) • Intracranial hemorrhage • Epidural hematoma • Paralysis • Seroma • CSF leakage • Temporary pain • Skin erosion around surface of implantation site * Patients must turn off device before CT scans, should avoid MRIs

  7. Resources:

More Related